The Business ReportTargacept's Lead Compound Ties PlaceboNovember 11, 2011 | David FordTargacept, with over 140 employees is the Piedmont Triad Research Park’s flagship biotech company. CEO, Don deBethizy spun the drug-discovery company out of R.J. Reynolds Tobacco Co. 11 years ago, and it’s been growing steadily ever since.
Targacept has an enormous pipeline of new drugs at various stages of completion that deal with brain disorders from Alzheimer’s to Parkinson’s. One of them is the company's lead compound, an antidepressant named TC-5214—its first to reach the final stage of clinical trials. On Tuesday, while still in that stage, 5214 met with a major set back.
Last week Business Journal Contributing Writer and Director of the Journalism Program at Wake Forest University Justin Catanoso spoke with deBethizy about the challenges and promise of bringing a new drug to market. Justin shared that conversation with WFDD’s David Ford. Full archive of The Business Report >>
|
WFDD News Archives
-
October 20, 2011: The Marriage of Roads, Bridges and Art
-
October 20, 2011: WSSU professor reacts to Gadhafi’s death (Keri Brown)
-
October 20, 2011: Independent Voters Want President's Attention (Keri Brown)
-
October 19, 2011: New Center in Winston-Salem Provides a Place to Stay for Patient’s Families (Keri Brown)
-
October 19, 2011: Occupy Winston-Salem, Greensboro Hit the Streets (David Ford)
-
October 19, 2011: Denton Offers Incentives, Puts People to Work (David Ford)
-
October 18, 2011: Obama Pushes Education in NC (Keri Brown)
|
